Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Safety and tolerability of the vepdegestrant in breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the Phase I dose escalation data from a Phase I/II study (NCT04072952) that aims to assess the safety and efficacy of vepdegestrant (ARV-471) in heavily pre-treated patients with ER2+/HER2- locally advanced or metastatic breast cancer. The drug was very well-tolerated: no dose-limiting toxicities were observed at any dose level. Of 83 patients, 24% had any grade of nausea. 24% experienced fatigue and 13% experienced arthralgia (all Grade 1 or 2). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.